Orphan designation: tipifarnib Treatment of peripheral T-cell lymphoma, 19/10/2020 Withdrawn

Orphan designation: tipifarnib Treatment of acute myeloid leukaemia, 10/03/2005 Withdrawn

Orphan designation: bemarituzumab Treatment of gastric cancer, 21/08/2024 Withdrawn

Orphan designation: 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid Treatment of systemic sclerosis, 12/03/2013 Withdrawn

Orphan designation: autologous adipose tissue-derived mesenchymal stem cells Treatment of thromboangiitis obliterans (Buerger's disease), 20/03/2017 Withdrawn

Orphan designation: nimorazole Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy, 23/02/2011 Withdrawn

Orphan designation: Lomitapide Treatment of familial chylomicronaemia, 17/12/2010 Withdrawn

Orphan designation: alpha-tocotrienol quinone Treatment of Leigh syndrome, 09/12/2011 Withdrawn

Orphan designation: (S)-1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide Treatment of fibrodysplasia ossificans progressiva, 18/07/2022 Withdrawn

Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals CMDh final position, 13/05/2026